TARGET-DERM: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions (Atopic Dermatitis)

Main inclusion criteria:1. Atopic Dermatitis with IGA ≥ 3 or use of biologics.

Target Pharmaceuticals
Principal Investigator(s)
Dr. Jonathan Silverberg
Request Information

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.